The use of fenofibrate in the management of patients with diabetic retinopathy: An evidence-based review

Australian Family Physician

Volumn 44, Issue 6, 2015, Pages 367-370

  Sharma, Neil ^a,b   Ooi, Ju Lee ^c   Ong, Jong ^a   Newman, Douglas ^a  

^a CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b WESTMEAD HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

FENOFIBRATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA;

AGONISTS; AUSTRALIA; COMPLICATION; DIABETIC RETINOPATHY; DISEASE COURSE; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS;

AUSTRALIA; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; DISEASE PROGRESSION; FENOFIBRATE; HUMANS; PPAR ALPHA;

EID: 84930749768     PISSN: 03008495     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Dunstan D, Zimmet P, Wellborn T, et al. Diabetes and associated disorders in Australia 2000. The Accelerating Epidemic. Australian diabetes, obesity and lifestyle report 2001. Melbourne: International Diabetes Institute, 2001.
2. Australian Bureau of Statistics. Diabetes in Australia: A Snapshot. Cat. no. 4820.0.55.00. Canberra: Commonwealth Government of Australia, 2009.
3. Barr E, Magliano P, Zimmet P, et al. The Australian diabetes, obesity and lifestyle study: tracking the accelerating epidemic, its causes and outcomes. Melbourne: International Diabetes Institute, 2005.
4. National Prescribing Service. RADAR: Rational Assessment of Drugs and Research. Australian Government Department of Health and Ageing, 2006. Available at www.nps.org.au/__data/assets/pdf_file/0003/14691/fenofibrate.pdf [Accessed 17 July 2014.].
5. Noonan JE, Jenkins AJ, Ma JX, Keech AC, Wang JJ, Lamoureux EL. An update on the molecular actions of fenofibrate and its clinical effects on diabetic retinopathy and other microvascular end points in patients with diabetes. Diabetes 2013;62:3968-75.
6. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study 27. Plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex. Diabetes Care 1997;20:1683-87.
7. Sasongko MB, Wong TY, Nguyen TT, et al. Serum apolipoproteins AI and B are stronger biomarkers of diabetic retinopathy than traditional lipids. Diabetes Care 2011;34:474-79.
8. Simó R, Hernández C. Fenofibrate for diabetic retinopathy. Lancet 2007;370:1667-68.
9. Wong TY, Simo R, Mitchell P. Fenofibrate-A potential systemic treatment for diabetic retinopathy? Am J Ophthalmol 2012;154:6-12.
10. Keech A, Simes RJ, Barter P, et al. FIELD study investigators. Effect of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-61.
11. Keech AC, Mitchell P, Summanen PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): A randomized controlled trial. Lancet 2007;370:1687-97.
12. The ACCORD Study Group. Action to control cardiovascular risk in diabetes (ACCORD) trial: Design and Methods. Am J Cardiol 2007;99[suppl]:21-33i.
13. The ACCORD Study Group. Effects of combination lipid therapy in type II diabetes mellitus. New Eng J Med 2010;362:1563-74.
14. The ACCORD Study Group and the ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes. New Eng J Med 2010;363:233-44.
15. Guo J, Meng F, Ma N, et al. Meta-analysis of safety of the coadministration of statin with fenofibrate in patients with combined hyperlipidaemia. Am J Cardiol 2012;110:1296-1301.
16. Lipidil (fenofibrate) product information, version 3. Available at www.medicines.org.au/files/abplipid.pdf [Accessed 10 July 2014].